뒤로
Hansa Biopharma AB (publ)(HNSBF) 가격
HNSBF 주가 차트
HNSBF 수입
Hansa Biopharma AB (publ)
$2.91
0%
$0
오늘 기준:Jan 26, 12:30:20 GMT-5
Earnings FAQ
HNSBF의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Hansa Biopharma AB (publ) HNSBF의 지난 분기 매출 실적은 어땠나요?
Hansa Biopharma AB (publ)의 매출 추정치는 얼마인가요?
Hansa Biopharma AB (publ)의 수익 품질 점수는 얼마인가요?
Hansa Biopharma AB (publ)는 언제 수익을 보고하나요?
Hansa Biopharma AB (publ)의 예상 수익은 얼마인가요?
Hansa Biopharma AB (publ)은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$2.91
시가
$2.91
일일 범위
$2.91 - $2.93
52주 범위
$2.73 - $4.58
거래량
150
평균 거래량
471
EPS(TTM)
-0.99
배당수익률
--
시가총액
$290.2M
HANSA BIOPHARMA AB란 무엇인가요?
Hansa Biopharma AB focuses on novel immunomodulatory enzymes, which treat rare immunoglobulin G-mediated autoimmune conditions, transplant rejection and cancer. The company is headquartered in Lund, Skane and currently employs 133 full-time employees. The company went IPO on 2007-10-17. The Company’s operations consist of research and development for drug discovery. The firm conducts several projects, among which primary are IdeS (Immunoglobulin G-degrading enzyme of Streptococcus pyogenes) and HBP-assay (Heparin Binding Protein-assay). IdeS’s goal is to enable transplantation that prevents antibody-mediated rejection. HBP-assay is a diagnostic method that aims to predict severe sepsis in patients with infectious disease symptoms. The Company’s patent portfolio consists of several patent families that geographically cover numerous jurisdictions, including the United States, Europe and Japan.